Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis. 1998 Jul; 178(1):70-9.

View in: PubMed

subject areas

Adult
Antigens
Anti-HIV Agents
B-Lymphocytes
CD4 Lymphocyte Count
Drug Therapy, Combination
Female
HIV Antigens
HIV Infections
HIV Protease Inhibitors
HIV-1
Humans
Hypersensitivity, Delayed
Lamivudine
Lymphocyte Activation
Lymphocyte Count
Male
Middle Aged
Reverse Transcriptase Inhibitors
Ritonavir
RNA, Viral
Time Factors
T-Lymphocyte Subsets
Zidovudine

authors with profiles

Alan L. Landay